Daiichi Sankyo Company Limited operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Daiichi Sankyo Company Limited with three other
companies in this sector in JAPAN :
Astellas Pharma Incorporated
sales of 1.30 trillion Japanese Yen [US$12.32 billion]
of which 97%
was Sales of Pharmaceuticals),
Eisai Company Limited
(695.62 billion Japanese Yen [US$6.59 billion]
of which 83%
was Pharmaceutical Business), and
Shionogi & Co Ltd
(333.37 billion Japanese Yen [US$3.16 billion]
of which 100%
was Prescription Drugs related business).
Daiichi Sankyo Company Limited reported sales of ¥981.79 billion (US$9.30 billion)
March of 2020.
increase of 5.6%
versus 2019, when the company's sales were ¥929.72 billion.
The sales level in 2020 was fairly close to the level five years ago: in 2015, Daiichi Sankyo Company Limited had sales
of ¥919.37 billion.
Sales of Prescription Drugs saw an increase
5.8% in 2020, from
¥861.12 billion to ¥911.26 billion.
Not all segments of Daiichi Sankyo Company Limited experienced an increase in sales in 2020:
sales of Other fell 4.3% to ¥2.13 billion.
(However, this segment's sales were only a very small portion of the company's overall sales).